Luciana Carota

Dr. Luciana Carota

DIMEC, Alma Mater Studiorum Università di Bologna, Bologna, Emilia-Romagna, Italy
orcid
Associate Researcher

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2005 in Journal of Atmospheric and Solar-Terrestrial Physics
Verified
Journal Article
Closed access
VSV. Sgrigna
V. Sgrigna
LCLuciana Carota
Luciana Carota
LCLivio Conti
Livio Conti
MCM. Corsi
M. Corsi
AGA.M. Galper
A.M. Galper
LSL. Stagni
L. Stagni

5 November 2024 in Blood
Verified
Journal Article
Closed access
GAGianluca Asti
Gianluca Asti
SDSaverio D'AMico
Saverio D'AMico
LCLuciana Carota
Luciana Carota
DPDavide Piscia
Davide Piscia
FCFrancesco Casadei
Francesco Casadei
FAFederico Alvarez
Federico Alvarez
BACKGROUND. Most oncological and non-oncological hematological conditions fall under the category of rare diseases. Rare diseases present unique challenges due to the limited availability of data, which impacts diagnostic rates and the generation of clinical evidence. Overall, they constitute a public health concern, highlighting the urgent need to develop new methods for improving data accessibility. In this context, Federated Learning (FL) is a Machine Learning approach that allows multiple centers to collaborate on complex research questions without the need to centralize or share data. This project was conducted by the Genomed4all and Synthema consortia with the goal of developing an innovative FL platform for rare hematological diseases. This platform enables the development of novel Artificial Intelligence (AI) models for personalized medicine without data sharing, to be implemented in the referral centers of EuroBloodNET, the European Reference Network for rare hematological diseases. The aims of the project were: 1) to develop robust federated models for personalized prediction using multicentric, real-world datasets; 2) to protect patients' privacy; and 3) to enhance collaboration between institutions while avoiding the creation of centralized data repositories. METHODS. The FL platform includes a manager node (MN) and multiple worker nodes (WN). Users upload their model to the MN, which distributes it to WNs for local training. Trained weights are returned to the MN for aggregation, repeating until training is complete. The MN is hosted at the Humanitas Research Hospital, and the 3 WNs are located at Humanitas, Universität Leipzig, and the University of Bologna. The testing approach is based on MOSAIC, an AI-based framework for multimodal analysis in rare cancers (PMID 38875514). We focused on myelodysplastic syndromes as a use case, since they are a rare hematological disease with high clinical and genomic heterogeneity (which represents a challenging scenario). The dataset includes comprehensive clinical and genomic data, with information on treatments and clinical outcomes. Each of the 3 WNs has a different sample size of patient data, with 2656, 1328, and 443 samples. Our goal was to build an AI-based model for prediction of survival probability, combining molecular information with clinical data. We planned 3 scenarios for testing: a best-case scenario using all available features, a worst-case scenario excluding up to 50% of genomic information, and a random scenario where an incremental percentage of the genomic variables were randomly removed. For each setting, a DeepSurv model is trained using 80% of local data for training and 20% for testing. RESULTS. In the best-case scenario, the model achieved a concordance index (c-index) of 0.75. The node with the smallest dataset initially registered the lowest c-index value (0.4); however, after the first training step, its performance began to follow the trend at levels comparable to the nodes with larger samples (0.54). In the random scenarios, the model still achieved a c-index of 0.75 but required more training rounds to converge. The same pattern was also observed in the worst-case scenario that was able to achieve a c-index of 0.74. The most relevant difference between the tested scenarios is the increased training time required to reach a good and stable performance when missing information is present. The developed technology is fully compliant with European GDPR regulations. In the upcoming months, the FL platform will be implemented in the referral centers of the EuroBloodNET clinical network. In addition to tabular data, we plan to address the federation of features extracted from medical images, including both histological slides and radiological scans (CT, MRI and PET-CT). CONCLUSION. The FL platform for rare hematological diseases allows multicentric training of AI models without sharing sensitive patient data. This approach ensures data privacy and security, addressing specific challenges associated with rare diseases. Moreover, this platform manages scenarios with missing data or variables, maintaining robustness and accuracy of predictive models. Overall, FL approach is expected to facilitate the development of more advanced and reliable healthcare solutions, paving the way toward personalized medicine in hematology.

28 July 2009 in Journal of Proteome Research
Verified
Journal Article
Closed access
LBLisa Bartoli
Lisa Bartoli
LMLUDOVICA MONTANUCCI
LUDOVICA MONTANUCCI
RFRaffaele Fronza
Raffaele Fronza
PMPier Luigi Martelli
Pier Luigi Martelli
Piero FariselliPiero Fariselli
Piero Fariselli
RCRita Casadio
Rita Casadio

20 January 2025 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Open access
CRCesare Rollo
Cesare Rollo
CPCorrado Pancotti
Corrado Pancotti
FSFlavio Sartori
Flavio Sartori
ICIsabella Caranzano
Isabella Caranzano
SDSaverio D’aMico
Saverio D’aMico
Tiziana SanaviaTiziana Sanavia
Tiziana Sanavia
Several computational pipelines for biomedical data have been proposed to stratify patients and to predict their prognosis through survival analysis. However, these analyses are usually performed independently, without integrating the information derived from each of them. Clustering of survival data is an underexplored problem, and current approaches are limited for biomedical applications, whose data are usually heterogeneous and multimodal, with poor scalability for high-dimensionality. We introduce VAE-Surv, a multimodal computational framework for patients' stratification and prognosis prediction. VAE-Surv integrates a Variational Autoencoder (VAE), which reduces the high-dimensional space characterizing the molecular data, with a deep survival model, which combines the embedded information with the clinical features. The VAE embedding step prioritizes local coherence within the feature space to detect potential nonlinear relationships among the molecular markers. The latent representation is then exploited to perform K-means clustering. To test the clinical robustness of the algorithm, VAE-Surv was applied to the Genomed4all cohort of Myelodysplastic Syndromes (MDS), comparing the identified subtypes with the World Health Organization (WHO) classification. The survival outcome was compared with the state-of-the-art Cox model and its penalized versions. Finally, to assess the generalizability of the results, the method was also validated on an external MDS cohort. Tested on 2,043 patients in the GenomMed4All cohort, VAE-Surv achieved a median C-index of 0.78, outperforming classical approaches. In addition, the latent space enhanced the clustering performance compared to a traditional approach that applies the clustering directly to the input data. Compared to the WHO 2016 MDS subtypes, the analysis of the identified clusters showed that the proposed framework can capture existing clinical categorizations while also suggesting novel, data-driven patient groups. Even tested in an external MDS cohort of 2,384 patients, VAE-Surv achieved a good prediction performance (median C-index=0.74), preserving the interpretability of the main clinical and genetic features. VAE-Surv enables automatic identification of patients' clusters, while outperforming the traditional CoxPH model in survival prediction tasks at the same time. Applied to MDS use case, the obtained genetic-based clusters exhibit a clear survival stratification, and the application of the clinical information allowed high performance in prognosis prediction.

2 February 2024 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
DDDaniele Dall'Olio
Daniele Dall'Olio
ESEric Sträng
Eric Sträng
ATAmin T Turki
Amin T Turki
JTJesse M Tettero
Jesse M Tettero
MBMartje Barbus
Martje Barbus
WCwith the HARMONY Healthcare Alliance Consortium
with the HARMONY Healthcare Alliance Consortium
Onco-hematological studies are increasingly adopting statistical mixture models to support the advancement of the genomically-driven classification systems for blood cancer. Targeting enhanced patients stratification based on the sole role of molecular biology attracted much interest and contributes to bring personalized medicine closer to reality. In onco-hematology, Hierarchical Dirichlet Mixture Models (HDMM) have become one of the preferred method to cluster the genomics data, that include the presence or absence of gene mutations and cytogenetics anomalies, into components. This work unfolds the standard workflow used in onco-hematology to improve patient stratification and proposes alternative approaches to characterize the components and to assign patient to them, as they are crucial tasks usually supported by a priori clinical knowledge. We propose (a) to compute the parameters of the multinomial components of the HDMM or (b) to estimate the parameters of the HDMM components as if they were Multivariate Fisher’s Non-Central Hypergeometric (MFNCH) distributions. Then, our approach to perform patients assignments to the HDMM components is designed to essentially determine for each patient its most likely component. We show on simulated data that the patients assignment using the MFNCH-based approach can be superior, if not comparable, to using the multinomial-based approach. Lastly, we illustrate on real Acute Myeloid Leukemia data how the utilization of MFNCH-based approach emerges as a good trade-off between the rigorous multinomial-based characterization of the HDMM components and the common refinement of them based on a priori clinical knowledge.

27 December 2011 in Neurocomputing
Verified
Journal Article
Closed access
LCLuciana Carota
Luciana Carota